Back to Journals » OncoTargets and Therapy » Volume 13

Genotyping on ctDNA Identifies Shifts in Mutation Spectrum Between Newly Diagnosed and Relapse/Refractory DLBCL

Authors Liu H, Yang C, Zhao X, Le J, Wu G, Wei J, Liang Y, Qian W

Received 3 August 2020

Accepted for publication 5 October 2020

Published 23 October 2020 Volume 2020:13 Pages 10797—10806

DOI https://doi.org/10.2147/OTT.S275334

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Prof. Dr. Takuya Aoki


Hui Liu,1,2,* Chunmei Yang,2,3,* Xiaoyan Zhao,2,4 Jing Le,5 Gongqiang Wu,6 Juying Wei,2,3 Yun Liang,1 Wenbin Qian1,2

1Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, People’s Republic of China; 2Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang 31003, People’s Republic of China; 3Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, People’s Republic of China; 4Department of Hematology, First Affiliated Hospital of Jiaxing University, Jianxing, Zhejiang 314000, People’s Republic of China; 5Department of Hematology, Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang 315000, People’s Republic of China; 6Department of Hematology, Dongyang Hospital Affiliated to Wenzhou Medical University, Dongyang People’s Hospital, Dongyang, Zhejiang 322100, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Wenbin Qian; Yun Liang
Department of Hematology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310009, People’s Republic of China
Tel +86-571-89713674
Email qianwb@zju.edu.cn; liangyun@zdu.edu.cn

Purpose: Diffuse large B cell lymphoma (DLBCL) is an aggressive B-cell malignancy with clinical and molecular heterogeneity whose genetics may have clinical implications for patient stratification and treatment. The circulating tumor DNA (ctDNA) is a novel noninvasive, real-time, and tumor-specific biomarker harboring tumor-derived genetic alterations that are identical to those of tumor cells, thus showing great promise in individualized medicine, including precise diagnosis, prediction of prognosis, response monitoring, and relapse detection for DLBCL.
Patients and Methods: In this study, we applied NGS analysis to tumor biopsies and ctDNA samples from 16 DLBCL subjects. Then, we compared the genomic alterations from 41 newly diagnosed patients and 56 relapsed/refractory (R/R) patients.
Results: Our results show that ctDNA can function as a liquid biopsy for tracking recurrently mutated genes in DLBCL (sensitivity: 87.50%). The mutational profiles of newly diagnosed and R/R DLBCL groups largely overlapped, but the frequencies of some gene mutations differ between the two cohorts. The distribution of mutations also revealed different frequencies in the two cohorts due to different signaling pathways. Genes from apoptosis pathway, immune response and BCR pathway suffered more mutations in R/R patients.
Conclusion: Overall, this study establishes ctDNA as an easily accessible source of tumor DNA for DLBCL genotyping and provides a deeper understanding of the somatic alteration spectrum for both newly diagnosed and R/R DLBCL patients.

Keywords: diffuse large B cell lymphoma, circulating tumor DNA, liquid biopsy, next-generation sequencing, mutation

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]